Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation
暂无分享,去创建一个
[1] E. Onaivi. Neuropsychobiological Evidence for the Functional Presence and Expression of Cannabinoid CB2 Receptors in the Brain , 2007, Neuropsychobiology.
[2] T. Bonner,et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[3] M. Racke. Experimental Autoimmune Encephalomyelitis (EAE) , 2001, Current protocols in neuroscience.
[4] V. Perry,et al. [The evidence for primary axonal loss in multiple sclerosis]. , 2000, Revista de neurologia.
[5] Li Zhu,et al. Methanandamide increases COX‐2 expression and tumor growth in murine lung cancer , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[6] S. Miller,et al. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. , 2003, The Journal of clinical investigation.
[7] P. Mcgeer,et al. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid‐type CB2 receptor , 2003, British journal of pharmacology.
[8] R. Chandra,et al. Elevated Inflammatory Markers in a Group of Amyotrophic Lateral Sclerosis Patients from Northern India , 2008, Neurochemical Research.
[9] T. Hamilton,et al. Effects of bacterial lipopolysaccharide on protein synthesis in murine peritoneal macrophages: Relationship to activation for macrophage tumoricidal function , 1986, Journal of cellular physiology.
[10] T. Freund,et al. Brain monoglyceride lipase participating in endocannabinoid inactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[11] D. Piomelli,et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. , 1997, Science.
[12] S. Wahl,et al. N-formylmethionyl peptides as chemoattractants for leucocytes. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[13] G. Cabral,et al. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance , 2005, Journal of leukocyte biology.
[14] J. Berman,et al. A role for CXCL12 (SDF-1α) in the pathogenesis of multiple sclerosis: Regulation of CXCL12 expression in astrocytes by soluble myelin basic protein , 2006, Journal of Neuroimmunology.
[15] S. Galiègue,et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. , 1995, European journal of biochemistry.
[16] G. Cabral,et al. delta-9-Tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmétte-Guérin-activated macrophages. , 1993, International journal of immunopharmacology.
[17] D. Dickson,et al. Neuropathological Diagnosis of Alzheimer’s Disease: A Perspective from Longitudinal Clinicopathological Studies , 1997, Neurobiology of Aging.
[18] S. Galiègue,et al. Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. , 1998, Blood.
[19] K. Mackie,et al. Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration , 2003, The Journal of Neuroscience.
[20] T. Klein,et al. Marijuana, immunity and infection , 1998, Journal of Neuroimmunology.
[21] N. Volkow,et al. In vivo imaging of the brain cannabinoid receptor. , 2002, Chemistry and physics of lipids.
[22] M. Herkenham,et al. Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[23] N. Kaminski,et al. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. , 1994, Biochemical pharmacology.
[24] J. Crow,et al. The CB2 cannabinoid agonist AM‐1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset , 2006, Journal of neurochemistry.
[25] T. Möller,et al. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival , 2005, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[26] I. Galve-Roperh,et al. R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. , 2006, Biochemical pharmacology.
[27] T. Bonner,et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. , 2000, European journal of pharmacology.
[28] C. Guaza,et al. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies , 2008, British journal of pharmacology.
[29] C. Raine,et al. Multiple Sclerosis: Remyelination in Acute Lesions , 1993, Journal of neuropathology and experimental neurology.
[30] J. Chambers,et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) , 2000, British journal of pharmacology.
[31] H. Friedman,et al. Modulation of Interleukin 2 Activity by Δ9-Tetrahydrocannabinol after Stimulation with Concanavalin A, Phytohemagglutinin, or Anti-CD3 Antibody , 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[32] S. Tauber,et al. Immune control by endocannabinoids — New mechanisms of neuroprotection? , 2007, Journal of Neuroimmunology.
[33] T. Hamilton,et al. The cell biology of macrophage activation. , 1984, Annual review of immunology.
[34] G. Cabral,et al. Effects on the immune system. , 2005, Handbook of experimental pharmacology.
[35] P. Casellas,et al. Cannabinoid-receptor expression in human leukocytes. , 1993, European journal of biochemistry.
[36] K. Mackie,et al. A Glial Endogenous Cannabinoid System Is Upregulated in the Brains of Macaques with Simian Immunodeficiency Virus-Induced Encephalitis , 2005, The Journal of Neuroscience.
[37] T. Bonner,et al. Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: immunochemical characterization by fusion protein antibodies , 1998, Journal of Neuroimmunology.
[38] D. Deutsch,et al. 2-arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. , 2000, Pharmacological research.
[39] C. Ali,et al. Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation , 2007, Molecular and Cellular Neuroscience.
[40] J. Schwartz,et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons , 1994, Nature.
[41] A. Howlett,et al. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. , 2000, Chemistry and physics of lipids.
[42] G. Nowak,et al. EEDQ, a tool for ex vivo measurement of occupancy of D-1 and D-2 dopamine receptors. , 1988, European journal of pharmacology.
[43] A. Szallasi. Vanilloid (capsaicin) receptors in health and disease. , 2002, American journal of clinical pathology.
[44] T. Mitchison,et al. Actin-Based Cell Motility and Cell Locomotion , 1996, Cell.
[45] B. Löwenberg,et al. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. , 2002, Blood.
[46] D. Gibson,et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.
[47] C. Newton,et al. Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. , 2001, European journal of pharmacology.
[48] C. Hillard,et al. Endocannabinoids in neuroimmunology and stress. , 2005, Current drug targets. CNS and neurological disorders.
[49] A. Howlett,et al. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. , 1984, Molecular pharmacology.
[50] A. Molleman,et al. Cannabinoid signalling (review) , 2006 .
[51] H. Heng,et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. , 1999, Brain research. Molecular brain research.
[52] V. Marzo,et al. Identification of Endocannabinoids and Related Compounds in Human Fat Cells , 2007, Obesity.
[53] K. Mackie,et al. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current , 2008, Proceedings of the National Academy of Sciences.
[54] J. Falck,et al. Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. , 2005, American journal of physiology. Heart and circulatory physiology.
[55] T. Klein,et al. Immunosuppression by Marijuana and Components , 1991 .
[56] A. Lackner,et al. Perivascular Macrophages Are the Primary Cell Type Productively Infected by Simian Immunodeficiency Virus in the Brains of Macaques , 2001, The Journal of experimental medicine.
[57] A. Howlett,et al. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. , 1986, Molecular pharmacology.
[58] S. Munro,et al. Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.
[59] C. Breivogel,et al. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. , 2000, Journal of neurochemistry.
[60] R. Pertwee. GPR55: a new member of the cannabinoid receptor clan? , 2007, British journal of pharmacology.
[61] L. Petrocellis,et al. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. , 1999, European journal of biochemistry.
[62] G. Cabral,et al. Cannabinoid-mediated exacerbation of brain infection by opportunistic amebae , 2004, Journal of Neuroimmunology.
[63] A. Howlett. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. , 1985, Molecular pharmacology.
[64] G. Cabral,et al. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. , 1999, The Journal of pharmacology and experimental therapeutics.
[65] G. Cabral,et al. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease , 1998, Journal of Neuroimmunology.
[66] G. O'neill,et al. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. , 1995, Molecular pharmacology.
[67] N. E. Buckley. The peripheral cannabinoid receptor knockout mice: an update , 2008, British journal of pharmacology.
[68] F. Mach,et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice , 2005, Nature.
[69] G. Cabral. Lipids as bioeffectors in the immune system. , 2005, Life sciences.
[70] L. Greensmith,et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delays disease progression in SOD1 mice , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[71] D. Baker,et al. In silico patent searching reveals a new cannabinoid receptor. , 2006, Trends in pharmacological sciences.
[72] S. Glaser,et al. Opposing Actions of Endocannabinoids on Cholangiocarcinoma Growth , 2007, Journal of Biological Chemistry.
[73] H. Hartung,et al. Matrix Metalloproteinases Exhibit Different Expression Patterns in Inflammatory Demyelinating Diseases of the Central and Peripheral Nervous System , 1999, Annals of the New York Academy of Sciences.
[74] C. Newton,et al. Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. , 1991, Journal of toxicology and environmental health.
[75] M. Glass,et al. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain , 2007, Neuroscience Letters.
[76] E. Benveniste. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis , 1997, Journal of Molecular Medicine.
[77] B. Dewald,et al. Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines. , 1994, Advances in immunology.
[78] D. Selkoe,et al. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease , 1998 .
[79] K. Mackie,et al. Cloning and molecular characterization of the rat CB2 cannabinoid receptor. , 2002, Biochimica et biophysica acta.
[80] C. Newton,et al. Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. , 2000, Journal of immunology.
[81] S. Arata,et al. Enhanced Growth of Legionella pneumophila in Tetrahydrocannabinol-Treated Macrophages , 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[82] P. Iribarren,et al. Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. , 2004, Cellular & molecular immunology.
[83] P. Sacerdote,et al. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro , 2005, Journal of Neuroimmunology.
[84] D. Clemente,et al. Cannabinoid CB1 and CB2 Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis , 2007, The Journal of Neuroscience.
[85] B. Juel-Jensen. Cannabis and recurrent herpes simplex. , 1972, British medical journal.
[86] J. Kehrl. Chemoattractant receptor signaling and the control of lymphocyte migration , 2006, Immunologic research.
[87] P. Casellas,et al. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. , 1996, European journal of biochemistry.
[88] N. Rothwell,et al. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide‐induced nitric oxide release in astrocyte cultures , 2002, Journal of neuroscience research.
[89] R. Ross. Anandamide and vanilloid TRPV1 receptors , 2003, British journal of pharmacology.
[90] V. Lagente,et al. Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. , 1997, European journal of pharmacology.
[91] Xavier Alvarez,et al. Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system , 2001, Glia.
[92] C. Gerard,et al. C5A anaphylatoxin and its seven transmembrane-segment receptor. , 1994, Annual review of immunology.
[93] B. Martin,et al. The Cannabinoid Delta-9-tetrahydrocannabinol Mediates Inhibition of Macrophage Chemotaxis to RANTES/CCL5: Linkage to the CB2 Receptor , 2008, Journal of Neuroimmune Pharmacology.
[94] R. Ransohoff,et al. The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.
[95] C. Breivogel,et al. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. , 2001, Molecular pharmacology.
[96] G. Cabral,et al. Delta‐9‐Tetrahydrocannabinol (THC), the Major Psychoactive Component of Marijuana, Exacerbates Brain Infection by Acanthamoeba , 2001, The Journal of eukaryotic microbiology.
[97] A. Buriani,et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[98] N. Davoust,et al. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. , 2008, The Journal of biological chemistry.
[99] M. Herkenham,et al. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. , 1994, The Journal of pharmacology and experimental therapeutics.
[100] T. Hamilton,et al. Molecular mechanisms of signal transduction in macrophages. , 1987, Immunology today.
[101] Y. Yamamoto,et al. Tetrahydrocannabinol inhibition of macrophage nitric oxide production. , 1996, Biochemical pharmacology.
[102] Y. Jeon,et al. Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. , 1996, Molecular pharmacology.
[103] D. Deutsch,et al. Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. , 2001, Molecular pharmacology.
[104] G. Mckhann,et al. Diseases of the Nervous System , 1905, The Hospital.
[105] A. Barbáchano,et al. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study , 2004, Synapse.
[106] P. Anand,et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord , 2006, BMC neurology.
[107] T. Bisogno,et al. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. , 1999, Biochemical and biophysical research communications.
[108] R. Blakely,et al. Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. , 2000, The Journal of pharmacology and experimental therapeutics.
[109] S. Smith,et al. Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus , 1979, Infection and immunity.
[110] Chang H. Kim. Chemokine-chemokine receptor network in immune cell trafficking. , 2004, Current drug targets. Immune, endocrine and metabolic disorders.
[111] H. Cottier,et al. Distinct chemokinetic and chemotactic responses in neutrophil granulocytes , 1978, European journal of immunology.
[112] P. Massi,et al. Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity. , 2000, European journal of pharmacology.
[113] G. Cabral,et al. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. , 1999, The Journal of pharmacology and experimental therapeutics.
[114] M. Kano,et al. Presynaptic Inhibition Caused by Retrograde Signal from Metabotropic Glutamate to Cannabinoid Receptors , 2001, Neuron.
[115] R. Ramer,et al. R(+)-methanandamide-induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. , 2004, Biochemical and biophysical research communications.
[116] Shuxian Hu,et al. Synthetic cannabinoid WIN55,212‐2 inhibits generation of inflammatory mediators by IL‐1β‐stimulated human astrocytes , 2005, Glia.
[117] E. Goetzl,et al. Specific binding of leukotriene B4 to receptors on human polymorphonuclear leukocytes. , 1982, Journal of immunology.
[118] H. Harris. Role of chemotaxis in inflammation. , 1954, Physiological reviews.
[119] N. Kaminski,et al. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. , 1992, Molecular pharmacology.
[120] M. Glass,et al. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. , 2007, Current neuropharmacology.
[121] C. Breivogel,et al. Levels, Metabolism, and Pharmacological Activity of Anandamide in CB1 Cannabinoid Receptor Knockout Mice , 2000 .
[122] T. Freund,et al. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. , 2002, Chemistry and physics of lipids.
[123] D. Hanahan. Platelet activating factor: a biologically active phosphoglyceride. , 1986, Annual review of biochemistry.
[124] J. Borrell,et al. Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis , 2003, The Journal of Neuroscience.
[125] G. Cabral,et al. Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. , 2001, Advances in experimental medicine and biology.
[126] W. Campbell,et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. , 2004, Molecular pharmacology.
[127] T. Ben-Hur,et al. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant , 1997, Journal of Neuroimmunology.
[128] R. Watson. Drugs of abuse and immune function , 1990 .
[129] M. Fujiwara,et al. New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application. , 2004, Journal of pharmacological sciences.
[130] N. Kaminski,et al. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. , 1997, Toxicology and applied pharmacology.
[131] D. Julius,et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway , 1997, Nature.
[132] P. Leigh,et al. Motor neuron disease. , 1994, Springer London.
[133] D. Kipmen-Korgun,et al. Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. , 2003, British journal of pharmacology.
[134] C. Velez-Pardo,et al. Avoidance of Abeta[(25-35)] / (H(2)O(2)) -induced apoptosis in lymphocytes by the cannabinoid agonists CP55,940 and JWH-015 via receptor-independent and PI3K-dependent mechanisms: role of NF-kappaB and p53. , 2006, Medicinal chemistry.
[135] M. Oz. Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. , 2006, Pharmacology & therapeutics.
[136] T. Klein. Cannabinoid-based drugs as anti-inflammatory therapeutics , 2005, Nature Reviews Immunology.
[137] R. Ganju,et al. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. , 2006, Molecular immunology.
[138] M. L. de Ceballos,et al. Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation , 2005, The Journal of Neuroscience.
[139] C. Newton,et al. Downregulation of cannabinoid receptor 2 (CB2) messenger RNA expression during in vitro stimulation of murine splenocytes with lipopolysaccharide. , 2001, Advances in experimental medicine and biology.
[140] Alberto Rábano,et al. Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains , 2003, The Journal of Neuroscience.
[141] G. Velasco,et al. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? , 2007, Trends in pharmacological sciences.
[142] Yun Bai,et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation , 2005, Journal of Neuroinflammation.
[143] C. Guaza,et al. The endogenous cannabinoid anandamide potentiates interleukin‐6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor‐mediated pathway , 1998, FEBS letters.
[144] Z. Vogel,et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.
[145] K. Waku,et al. 2-Arachidonoylglycerol Induces the Migration of HL-60 Cells Differentiated into Macrophage-like Cells and Human Peripheral Blood Monocytes through the Cannabinoid CB2 Receptor-dependent Mechanism* , 2003, Journal of Biological Chemistry.
[146] J. Laitinen,et al. Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. , 2004, Biochemical pharmacology.
[147] G. Griffin,et al. Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. , 2000, The Journal of pharmacology and experimental therapeutics.
[148] D. Kipmen-Korgun,et al. Anandamide initiates Ca2+ signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells , 2003 .
[149] K. Waku,et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. , 2004, Journal of biochemistry.
[150] B. Martin,et al. Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. , 2002, Chemistry and physics of lipids.
[151] P. Casellas,et al. Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. , 1999, The Journal of biological chemistry.
[152] C. Murdoch,et al. Chemokine receptors and their role in inflammation and infectious diseases. , 2000, Blood.
[153] R. Watson,et al. Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. , 1991, Advances in experimental medicine and biology.
[154] C. Newton,et al. Δ9-Tetrahydrocannabinol Treatment Suppresses Immunity and Early IFN-γ, IL-12, and IL-12 Receptor β2 Responses to Legionella pneumophila Infection1 , 2000, The Journal of Immunology.
[155] S. Hjorth,et al. The orphan receptor GPR55 is a novel cannabinoid receptor , 2007, British journal of pharmacology.
[156] P. Sacerdote,et al. In vivo and in vitro treatment with the synthetic cannabinoid CP55,940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors , 2000, Journal of Neuroimmunology.
[157] Motor neuron disease. , 1994 .
[158] G. Cabral,et al. Delta-9-tetrahydrocannabinol inhibits macrophage protein expression in response to bacterial immunomodulators. , 1989, Journal of toxicology and environmental health.
[159] S. Arata,et al. Tetrahydrocannabinol treatment suppresses growth restriction of Legionella pneumophila in murine macrophage cultures. , 1991, Life sciences.
[160] R. Price,et al. Human immunodeficiency virus and the central nervous system. , 1992, Annual review of microbiology.
[161] G. Uhl,et al. Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain , 2006, Brain Research.
[162] G. Cabral,et al. Acanthamoeba spp. as Agents of Disease in Humans , 2003, Clinical Microbiology Reviews.
[163] C. Newton,et al. Cannabinoid receptors and immunity. , 1998, Immunology today.
[164] D. Julius,et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide , 1999, Nature.
[165] B Dewald,et al. Human chemokines: an update. , 1997, Annual review of immunology.
[166] E. Ponomarev,et al. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli , 2005, Journal of neurochemistry.
[167] G. Cabral,et al. CB2 receptors in the brain: role in central immune function , 2008, British journal of pharmacology.
[168] P. Sonneveld,et al. Distinct Expression Profiles of the Peripheral Cannabinoid Receptor in Lymphoid Tissues Depending on Receptor Activation Status 1 , 2004, The Journal of Immunology.
[169] T. Groblewski,et al. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models , 2003, The European journal of neuroscience.
[170] S. Miller,et al. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212 , 2003 .
[171] F. Entschladen,et al. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes , 2004, Cancer Immunology, Immunotherapy.
[172] R. Ellis,et al. Human immunodeficiency virus and the central nervous system. , 2006, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.
[173] M. Herkenham,et al. Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains , 1994, Neuroscience.
[174] D. Selkoe. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. , 1998, Trends in cell biology.
[175] Z. Vogel,et al. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling , 1995, FEBS letters.
[176] D Giulian,et al. Characterization of ameboid microglia isolated from developing mammalian brain , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[177] P. Casellas,et al. Cannabinoids enhance human B‐cell growth at low nanomolar concentrations , 1995, FEBS letters.
[178] T. Jin,et al. Moving toward understanding eukaryotic chemotaxis. , 2006, European journal of cell biology.
[179] C. Newton,et al. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection , 1994, Infection and immunity.
[180] K. Mackie,et al. Identification functional characterization of brainstem cannabinoid CB2 receptors. , 2022 .
[181] D. Lauffenburger,et al. Cell Migration: A Physically Integrated Molecular Process , 1996, Cell.
[182] A. Arévalo-Martı́n,et al. The endocannabinoid system modulates a transient TNF pathway that induces neural stem cell proliferation , 2008, Molecular and Cellular Neuroscience.
[183] S. Mancham,et al. Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. , 1997, Blood.
[184] G. Cabral,et al. Cannabinoids inhibit LPS‐inducible cytokine mRNA expression in rat microglial cells , 2000, Glia.
[185] T. Bonner,et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.
[186] E. S. Graham,et al. Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! , 2008, Journal of Neuroscience Methods.
[187] G. Kreutzberg. Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.
[188] G. Cabral,et al. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. , 2002, International immunopharmacology.
[189] G. Uhl,et al. Discovery of the Presence and Functional Expression of Cannabinoid CB2 Receptors in Brain , 2006, Annals of the New York Academy of Sciences.